To support the development of a broadly applicable therapy directed at modulating host factors and immune-mediated processes to reduce lung injury and immunopathology in serious influenza.
IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
-
Activity
N43
-
Administering IC
AI
-
Application Type
-
Direct Cost Amount
-
Indirect Cost Amount
-
Total Cost
225000
-
Sub Project Total Cost
-
ARRA Funded
False
-
CFDA Code
855
-
Ed Inst. Type
-
Funding ICs
NIAID:225000\
-
Funding Mechanism
SBIR/STTR Contracts
-
Study Section
-
Study Section Name